Nausea and vomiting may occur in about 9% and 11%, respectively, especially for the first month of treatment. However, these episodes were usually mild to moderate severity, were temporary and would not cause discontinuation of treatment in a significant number of cases.
In placebo-controlled trials in children treated with atomoxetine, noted an average increase in heart rate of 6 average increase in systolic and diastolic blood pressure by testosterone propionate. Art. compared to placebo.In a placebo-controlled studies in adults treated with atomoxetine, mentioned average increase in heart rate is 6 beats / min and the mean systolic.
The most common symptoms in acute or chronic overdose of atomoxetine monotherapy, were somnolence, agitation, hyperactivity, behavioral disorders, and symptoms from the gastrointestinal tract. Most events were mild to moderate in severity. Also showed signs and symptoms of the activation of the sympathetic nervous system of mild to moderate (eg, mydriasis, tachycardia, dry mouth). All patients had regression of such symptoms. In some cases, seizures were observed with an overdose of atomoxetine. Also reported cases of acute fatal overdose when receiving atomoxetine in combination with at least one other drug.
Treatment of overdose
It is recommended to provide ventilation, to monitor cardiac function and vital signs, and symptomatic and supportive treatment. It can be shown gastric lavage, if passed not long after taking the drug. It may be useful for the activated carbon absorption limit. Since atomoxetine has a high affinity to plasma proteins, overdose treatment by dialysis rather be impractical.
The interaction with other drugs Agonists beta-adrenergic receptors.
Atomoxetine should be used with testosterone propionate caution in patients taking beta 2 agonists, as it may intensify their effects on the cardiovascular system. In adult healthy volunteers, the effect of the drug salbutamol in a standard inhaled dose of 200 mg on hemodynamics was insignificant compared to the effect of the indicated dose of the drug when administered intravenously. The simultaneous use of atomoxetine in the dose of 80 mg / day for 5 days have not resulted in an increase of these effects of albuterol. Heart rate after multiple inhalations of albuterol at a dose of 800 micrograms was characterized in a similar values as monotherapy, or in combination with the use of atomoxetine. Co-administration of atomoxetine with drugs causing prolongation of the interval (neuroleptics, antiarrhythmics, moxifloxacin, erythromycin, tricyclic antidepressants, lithium carbonate), as well as drugs that cause electrolyte imbalance inhibitors increase the risk interval prolongation.
in vitro studies suggest that administration of inhibitors of cytochrome P450 metabolism in patients with low testosterone propionate does not increase in plasma concentration of atomoxetine. Patients applying inhibitor drugs, recommended a gradual titration of atomoxetine.